Stryker (SYK) PT Raised to $184.00 at Leerink Swann

Stryker (NYSE:SYK) had its price target upped by equities researchers at Leerink Swann from $177.00 to $184.00 in a research report issued on Wednesday. The firm presently has an “outperform” rating on the medical technology company’s stock. Leerink Swann’s price target points to a potential upside of 11.52% from the company’s previous close.

Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $161.00 to $173.00 in a report on Thursday, November 16th. BMO Capital Markets upgraded shares of Stryker to a “market perform” rating and set a $163.00 price target for the company in a report on Tuesday, December 12th. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, SunTrust Banks restated a “buy” rating and set a $161.00 price target on shares of Stryker in a report on Friday, November 17th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $159.85.

Shares of Stryker (SYK) traded down $3.45 on Wednesday, hitting $165.00. 662,340 shares of the company’s stock traded hands, compared to its average volume of 1,244,731. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market capitalization of $63,152.60, a PE ratio of 35.26, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. Stryker has a one year low of $121.86 and a one year high of $170.00.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $1.78 earnings per share. sell-side analysts forecast that Stryker will post 6.48 EPS for the current year.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYK. Acrospire Investment Management LLC bought a new position in shares of Stryker in the second quarter valued at approximately $111,000. Sawyer & Company Inc bought a new position in shares of Stryker in the fourth quarter valued at approximately $125,000. Sit Investment Associates Inc. raised its position in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares during the period. Oak Point Wealth Management bought a new position in shares of Stryker in the fourth quarter valued at approximately $145,000. Finally, San Francisco Sentry Investment Group CA raised its position in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the period. Hedge funds and other institutional investors own 74.94% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Stryker (SYK) PT Raised to $184.00 at Leerink Swann” was originally posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/31/stryker-syk-pt-raised-to-184-00-at-leerink-swann.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)